Skip to content

Selection of a Protective T Cell-based HIV-1/FIV Vaccine

Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02389595
Enrollment
270
Registered
2015-03-17
Start date
2015-05-01
Completion date
2028-05-01
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, vaccine, T cell

Brief summary

The purpose of this research study is to develop a vaccine against Human immunodeficiency virus (HIV), a disease that causes AIDS in people,. The investigator will be looking at viruses similar to HIV in animals. Since these viruses are very similar to HIV, the blood from humans who have been exposed to HIV will be tested to see if the immune system will recognize the HIV and prevent infection. HIV targets the immune system by attacking certain T cells called CD4+ T cells. There are parts on the AIDS viruses that help the virus infect these cells and other parts that help the immune system prevent viral infection by activating protective T-cells that fight HIV. Different T-cell populations are very important in most vaccines as they act as "effectors" that work as part of the immune system to recognize and fight off HIV infection. When effector T cells are activated by appropriate "protective" part(s) of the virus they either block HIV from reproducing or kill HIV infected cells. By finding these common protective parts of each of these human and animal AIDS viruses, the investigator hopes to make a vaccine that helps the immune system prevent HIV infection by avoiding parts that attack CD4+ T cells and may worsen HIV infection and selecting for parts that stimulate effector T cells that fight HIV infection.

Detailed description

As a participant in this study a blood drawn will performed.

Interventions

OTHERHIV positive subjects

This group will provide a blood sample.

OTHERNon-infected control subjects

This group will be de-identified blood samples from a commercial source.

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male and female subjects between 18 and 65 years old who are HIV positive

Exclusion criteria

* Persons with other immune diseases that would result in autoimmunity or aberrant immune responses (such as subjects who have undergone chemotherapy within the past year).

Design outcomes

Primary

MeasureTime frame
T cell proliferation in response to viral epitopes120 hours (5 days)

Secondary

MeasureTime frame
Cytokine production in response to viral epitopes24 hours (1 day)
Cytotoxin production in response to viral epitopes8 hours

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJanet K Yamamoto, PhD

University of Florida

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026